JP2024502036A5 - - Google Patents
Info
- Publication number
- JP2024502036A5 JP2024502036A5 JP2023539978A JP2023539978A JP2024502036A5 JP 2024502036 A5 JP2024502036 A5 JP 2024502036A5 JP 2023539978 A JP2023539978 A JP 2023539978A JP 2023539978 A JP2023539978 A JP 2023539978A JP 2024502036 A5 JP2024502036 A5 JP 2024502036A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- nucleic acid
- manipulated
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063131987P | 2020-12-30 | 2020-12-30 | |
| US63/131,987 | 2020-12-30 | ||
| PCT/US2021/065524 WO2022147133A1 (en) | 2020-12-30 | 2021-12-29 | Engineered t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502036A JP2024502036A (ja) | 2024-01-17 |
| JP2024502036A5 true JP2024502036A5 (https=) | 2025-01-10 |
Family
ID=80050925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539978A Pending JP2024502036A (ja) | 2020-12-30 | 2021-12-29 | 操作されたｔ細胞 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240316100A1 (https=) |
| EP (1) | EP4271799A1 (https=) |
| JP (1) | JP2024502036A (https=) |
| KR (1) | KR20230153356A (https=) |
| CN (1) | CN116848235A (https=) |
| AU (1) | AU2021411521A1 (https=) |
| CA (1) | CA3206484A1 (https=) |
| IL (1) | IL304069A (https=) |
| MX (1) | MX2023007801A (https=) |
| TW (1) | TW202235615A (https=) |
| WO (1) | WO2022147133A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024006955A1 (en) * | 2022-06-29 | 2024-01-04 | Intellia Therapeutics, Inc. | Engineered t cells |
| CN115873128A (zh) * | 2022-10-14 | 2023-03-31 | 武汉波睿达生物科技有限公司 | 一种靶向表达dsg3表面抗原细胞的融合嵌合抗原受体修饰的t细胞及其应用 |
| CN116042676A (zh) * | 2023-01-04 | 2023-05-02 | 上海南方模式生物科技股份有限公司 | 一种基于CRISPR-Cas9构建TNF-α-HiBit动物模型的方法 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137439A2 (en) * | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Engineered t cells |
| CN121558712B (zh) * | 2026-01-26 | 2026-04-03 | 四川大学 | 基于荧光互补筛选细菌膜蛋白折叠机器靶向抑制剂的方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| JPH10500310A (ja) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ |
| EP2526199A4 (en) | 2010-01-22 | 2013-08-07 | Scripps Research Inst | PROCESS FOR PRODUCING ZINC FINGERUCLEASES WITH CHANGED EFFECT |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| AU2013335451C1 (en) | 2012-10-23 | 2024-07-04 | Toolgen Incorporated | Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US20150376586A1 (en) | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| WO2016106121A1 (en) | 2014-12-23 | 2016-06-30 | Syngenta Participations Ag | Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| US11279928B2 (en) | 2015-06-29 | 2022-03-22 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
| WO2017093969A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| SG10202106058WA (en) | 2016-12-08 | 2021-07-29 | Intellia Therapeutics Inc | Modified guide rnas |
| EP4029943A1 (en) | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| WO2019067910A1 (en) | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| CN119662544A (zh) * | 2018-03-14 | 2025-03-21 | 湖南思为康医药有限公司 | 用于降低毒性的免疫细胞修饰以及其在过继细胞疗法中的用途 |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| CN113227374A (zh) | 2018-10-16 | 2021-08-06 | 因特利亚治疗公司 | 用于免疫疗法的组合物和方法 |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| EP3980035A4 (en) * | 2019-06-07 | 2023-08-23 | The Board Of Trustees Of The Leland Stanford Junior University | FOXP-ENGINEERED CD4+ T-CELLS FOR USE IN TREG-BASED IMMUNOTHERAPY |
-
2021
- 2021-12-29 CN CN202180093689.5A patent/CN116848235A/zh active Pending
- 2021-12-29 TW TW110149370A patent/TW202235615A/zh unknown
- 2021-12-29 EP EP21848454.1A patent/EP4271799A1/en active Pending
- 2021-12-29 KR KR1020237025734A patent/KR20230153356A/ko active Pending
- 2021-12-29 MX MX2023007801A patent/MX2023007801A/es unknown
- 2021-12-29 US US18/270,261 patent/US20240316100A1/en active Pending
- 2021-12-29 JP JP2023539978A patent/JP2024502036A/ja active Pending
- 2021-12-29 CA CA3206484A patent/CA3206484A1/en active Pending
- 2021-12-29 IL IL304069A patent/IL304069A/en unknown
- 2021-12-29 AU AU2021411521A patent/AU2021411521A1/en active Pending
- 2021-12-29 WO PCT/US2021/065524 patent/WO2022147133A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024502036A5 (https=) | ||
| US20240033300A1 (en) | Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene | |
| Huang et al. | Airway inflammation and IgE production induced by dust mite allergen-specific memory/effector Th2 cell line can be effectively attenuated by IL-35 | |
| JP2020509780A5 (https=) | ||
| JP2021525518A (ja) | 細胞をゲノム編集及び活性化するための方法 | |
| JP2021503902A (ja) | ポリペプチド | |
| JP2021521849A5 (https=) | ||
| JP2023138660A5 (https=) | ||
| JP2023533979A (ja) | ヒト自然免疫機能を支えるトランスジェニックマウスモデル | |
| WO2019154313A1 (zh) | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 | |
| US20220133792A1 (en) | Signaling platforms for chimeric antigen receptor t cells | |
| JP2023524853A5 (https=) | ||
| JP2021515576A5 (https=) | ||
| IL299491A (en) | Methods and compositions for editing the b2m locus in b cells | |
| CN111499766A (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| CN118108856A (zh) | 靶向cd5分子的嵌合抗原受体nk细胞及其抗肿瘤应用 | |
| JP2025509974A (ja) | 免疫不全ｆｃｇｒ１ノックアウトマウスモデル | |
| US20230272431A1 (en) | Methods and compositions for editing the b2m locus in b cells | |
| Arjomandnejad et al. | eScholarship@ UMassChan | |
| WO2025231213A2 (en) | Modified b cells and methods for use thereof | |
| US20250369020A1 (en) | Production and/or delivery of multispecific binding agents | |
| US20220387493A1 (en) | Method for producing cytotoxic effector memory t-cells for car t-cell treatment of cancer | |
| Kaur et al. | IMMUNOTHERAPY IN SPECIFIC AUTOIMMUNE DISEASES | |
| WO2024256842A1 (en) | Therapeutic transfection | |
| Bukulmez | Mesenchymal stem cell treatment in mice models of systemic lupus erythematosus |